Co‐targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor‐resistant melanoma
View/ Open
Author
Echevarría‐Vargas, Ileabett M
Reyes‐Uribe, Patricia I
Guterres, Adam N
Yin, Xiangfan
Kossenkov, Andrew V
Liu, Qin
Zhang, Gao
Krepler, Clemens
Cheng, Chaoran
Wei, Zhi
Somasundaram, Rajasekharan
Karakousis, Giorgos
Xu, Wei
Morrissette, Jennifer JD
Lu, Yiling
Mills, Gordon B
Benchun, Miao
Frederick, Dennie T
Weeraratna, Ashani T
Herlyn, Meenhard
Amaravadi, Ravi
Schuchter, Lynn M
Burd, Christin E
Aplin, Andrew E
Xu, Xiaowei
Villanueva, Jessie
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.15252/emmm.201708446Metadata
Show full item recordCitation
Echevarría‐Vargas, I. M., P. I. Reyes‐Uribe, A. N. Guterres, X. Yin, A. V. Kossenkov, Q. Liu, G. Zhang, et al. 2018. “Co‐targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor‐resistant melanoma.” EMBO Molecular Medicine 10 (5): e8446. doi:10.15252/emmm.201708446. http://dx.doi.org/10.15252/emmm.201708446.Abstract
Abstract Despite novel therapies for melanoma, drug resistance remains a significant hurdle to achieving optimal responses. NRAS‐mutant melanoma is an archetype of therapeutic challenges in the field, which we used to test drug combinations to avert drug resistance. We show that BET proteins are overexpressed in NRAS‐mutant melanoma and that high levels of the BET family member BRD4 are associated with poor patient survival. Combining BET and MEK inhibitors synergistically curbed the growth of NRAS‐mutant melanoma and prolonged the survival of mice bearing tumors refractory to MAPK inhibitors and immunotherapy. Transcriptomic and proteomic analysis revealed that combining BET and MEK inhibitors mitigates a MAPK and checkpoint inhibitor resistance transcriptional signature, downregulates the transcription factor TCF19, and induces apoptosis. Our studies demonstrate that co‐targeting MEK and BET can offset therapy resistance, offering a salvage strategy for melanomas with no other therapeutic options, and possibly other treatment‐resistant tumor types.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5938620/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:37160047
Collections
- HMS Scholarly Articles [17922]
Contact administrator regarding this item (to report mistakes or request changes)